Wells Fargo’s Checkpoint Therapeutics CKPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-1,000
Closed -$4.04K 7166
2025
Q1
$4.04K Hold
1,000
﹤0.01% 6056
2024
Q4
$3.2K Hold
1,000
﹤0.01% 6128
2024
Q3
$2.24K Sell
1,000
-2,000
-67% -$4.62K ﹤0.01% 6043
2024
Q2
$6.45K Sell
3,000
-159
-5% -$283 ﹤0.01% 5830
2024
Q1
$6.48K Sell
3,159
-13,979
-82% -$27.9K ﹤0.01% 5846
2023
Q4
$39.2K Buy
17,138
+999
+6% +$2.17K ﹤0.01% 5363
2023
Q3
$27.4K Buy
16,139
+8,243
+104% +$18.7K ﹤0.01% 5468
2023
Q2
$19.5K Buy
7,896
+6,018
+320% +$16.4K ﹤0.01% 5747
2023
Q1
$4.23K Buy
1,878
+1,829
+3,733% +$9.18K ﹤0.01% 6093
2022
Q4
$250 Buy
49
+1
+2% +$7 ﹤0.01% 6554
2022
Q3
$0 Buy
48
+2
+4% +$24 ﹤0.01% 6723
2022
Q2
$0 Sell
46
-138
-75% -$1.81K ﹤0.01% 6862
2022
Q1
$3K Buy
184
+145
+372% +$3.11K ﹤0.01% 6570
2021
Q4
$1K Buy
39
+1
+3% +$33 ﹤0.01% 6977
2021
Q3
$1K Sell
38
-2
-5% -$59 ﹤0.01% 6671
2021
Q2
$1K Sell
40
-4,945
-99% -$137K ﹤0.01% 6631
2021
Q1
$157K Sell
4,985
-8,758
-64% -$294K ﹤0.01% 5271
2020
Q4
$364K Buy
13,743
+1,423
+12% +$36K ﹤0.01% 4751
2020
Q3
$330K Buy
12,320
+976
+9% +$23.4K ﹤0.01% 4649
2020
Q2
$224K Buy
11,344
+7,520
+197% +$137K ﹤0.01% 4838
2020
Q1
$57K Sell
3,824
-76
-2% -$1.34K ﹤0.01% 5289
2019
Q4
$67K Buy
3,900
+1
+0% +$17 ﹤0.01% 5424
2019
Q3
$97K Buy
3,899
+3,882
+22,835% +$107K ﹤0.01% 5331
2019
Q2
$1K Buy
+17
New +$667 ﹤0.01% 6235

Wells Fargo's CKPT Position: Q2 2025 in Review

Wells Fargo sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 1,000 shares — an estimated $4.04K sold.

Wells Fargo first reported a position in CKPT in Q2 2019 and held it in 24 quarters. The position peaked at $364K in Q4 2020. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.

  • Wells Fargo reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wells Fargo sold 1,000 Checkpoint Therapeutics shares in Q2 2025, an estimated $4.04K.
  • Wells Fargo first reported a position in Checkpoint Therapeutics in Q2 2019 and held it in 24 quarters.
  • Wells Fargo's Checkpoint Therapeutics position peaked at $364K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.

Based on Wells Fargo's 13F filing for Q2 2025, filed 14 Aug 2025.